ENDOCYTE INC 4
4 · ENDOCYTE INC · Filed Aug 8, 2013
Insider Transaction Report
Form 4
ENDOCYTE INCECYT
Lovejoy Chandra D
VP of Regulatory Affairs
Transactions
- Exercise/Conversion
Common Stock
2013-08-06$3.05/sh+6,130$18,697→ 6,130 total - Exercise/Conversion
Common Stock
2013-08-06$2.54/sh+655$1,664→ 7,000 total - Exercise/Conversion
Stock Option (right to buy)
2013-08-06−6,130→ 479 totalExercise: $3.05Exp: 2017-11-14→ Common Stock (6,130 underlying) - Exercise/Conversion
Common Stock
2013-08-06$2.54/sh+215$546→ 6,345 total - Exercise/Conversion
Stock Option (right to buy)
2013-08-06−215→ 0 totalExercise: $2.54Exp: 2019-03-05→ Common Stock (215 underlying) - Exercise/Conversion
Stock Option (right to buy)
2013-08-06−655→ 0 totalExercise: $2.54Exp: 2019-08-13→ Common Stock (655 underlying) - Sale
Common Stock
2013-08-06$17.29/sh−7,000$121,030→ 0 total
Footnotes (4)
- [F1]Shares subject to the option vested 50% on November 14, 2009 and monthly over a period of 24 months beginning on November 30, 2009.
- [F2]Shares subject to the option vested monthly over a period of 48 months beginning on March 31, 2009.
- [F3]Shares subject to the option vested monthly over a period of 48 months beginning on August 31, 2009.
- [F4]Represents the sale of 7,000 shares in multiple transactions, ranging in price from $17.2701 to $17.35 per share, resulting in a weighted average sale price per share of $17.29. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range.